<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01299285</url>
  </required_header>
  <id_info>
    <org_study_id>14010</org_study_id>
    <secondary_id>I4V-MC-JADG</secondary_id>
    <nct_id>NCT01299285</nct_id>
  </id_info>
  <brief_title>Disposition of 14C-LY3009104 Following Oral Administration in Healthy Human Subjects</brief_title>
  <official_title>Disposition of 14C-LY3009104 Following Oral Administration in Healthy Human Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single dose study of radiolabeled [14C]-LY3009104 in healthy male volunteers to
      study the absorption, distribution, metabolism, and elimination of LY3009104. This study
      requires minimum of 7 days and maximum of 22 days stay. This study is for research purposes
      only and is not intended to treat any medical condition.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of the Total Radioactive Dose Administered Excreted From Urine and Feces</measure>
    <time_frame>Baseline up to 120 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetics: LY3009104 Area Under the Concentration-Time Curve From Time Zero to Infinity [AUC(0-∞)]</measure>
    <time_frame>Baseline up to 48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetics: Radioactivity Area Under the Concentration-Time Curve From Time Zero to Infinity [AUC(0-∞)]</measure>
    <time_frame>Baseline up to 48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetics: Maximum Observed LY3009104 Concentration (Cmax)</measure>
    <time_frame>Baseline up to 48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetics: Maximum Observed Radioactivity Concentration (Cmax)</measure>
    <time_frame>Baseline up to 48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetics: LY3009104 and Radioactivity Time to Maximum Observed Concentration (Tmax)</measure>
    <time_frame>Baseline up to 48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Dose of LY3009104 and LY3009104 Metabolites in Urine</measure>
    <time_frame>Baseline up to 48 hours</time_frame>
    <description>Percentages of LY3009104 (parent) and LY3009104 metabolites that were excreted in the urine are reported. Only those metabolites that were detectable in the urine are included in the report.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Dose of LY3009104 and LY3009104 Metabolites in Feces</measure>
    <time_frame>Baseline up to 72 hours</time_frame>
    <description>Percentages of LY3009104 (parent) and LY3009104 metabolites that were excreted in the feces are reported. Only those metabolites that were detectable in the feces are included in the report.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Total Radioactivity of LY3009104 and LY3009104 Metabolites in Plasma</measure>
    <time_frame>Baseline up to 24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>LY3009104</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single 10-milligram (mg) oral dose containing 100 microcuries of 14C-labeled LY3009104</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3009104</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>LY3009104</arm_group_label>
    <other_name>Baricitinib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Overtly healthy males, as determined by medical history and physical examination

          -  Will either be sterile or, if sexually active, agree to use a reliable method of birth
             control from check-in until 3 months after the end of the study

          -  Body mass index (BMI) between 19 and 30 kilogram/square meter (kg/m²)

          -  Experience on average 1 to 2 bowel movements per day

          -  Clinical laboratory test results within the normal reference range for the clinical
             research unit (CRU) or, results with acceptable deviations which are judged to be not
             clinically significant by the investigator

          -  Normal blood pressure and heart rate (sitting) as determined by the investigator

          -  Venous access sufficient to allow blood sampling

          -  Are reliable and willing to make themselves available for the duration of the study,
             and are willing to abide by the CRU policies and procedures, and study restrictions

          -  Have given written informed consent approved by Lilly and the Institutional Review
             Board (IRB) governing the CRU

        Exclusion Criteria:

          -  Are currently enrolled in, have completed or discontinued, a clinical trial involving
             an investigational product or are concurrently enrolled in any other type of medical
             research judged not to be scientifically, or medically compatible with this study

          -  Have known allergies to LY3009104, related compounds, or any components of the
             formulation

          -  Have previously received the investigational product in this study, have completed or
             withdrawn from this study or any other study investigating LY3009104

          -  History or presence of an abnormality in the 12-lead electrocardiogram (ECG) that, in
             the opinion of the investigator, is clinically significant

          -  Current or recent history (&lt;30 days prior to Screening and/or &lt;45 days prior to
             Check-in) of a clinically significant bacterial, fungal, parasitic, viral (not
             including rhinopharyngitis), or mycobacterial infection

          -  An Absolute Neutrophil Count (ANC) less than 2000 cells/microliter. For abnormal
             values a single repeat will be allowed

          -  Have a history or presence of cardiovascular, respiratory, hepatic, renal,
             gastrointestinal, endocrine, hematological, or neurological disorders capable of
             significantly altering the absorption, metabolism, or elimination of drugs; of
             constituting a risk when taking the study medication; or of interfering with the
             interpretation of data

          -  Show evidence of significant active neuropsychiatric disease and in particular
             evidence of significant medical or psychiatric illness within the past 12 months

          -  Have known substance dependence or abuse within 6 months prior to the study (according
             to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition [DSM-IV]
             diagnosis), or regularly use known drugs of abuse and/or show positive findings on
             urinary drug screening

          -  Show evidence of human immunodeficiency virus (HIV) infection and/or positive human
             HIV antibodies

          -  Show evidence of hepatitis C and/or positive hepatitis C antibody

          -  Evidence hepatitis B (active or surface antigen positive [HBsAg+]) or hepatitis B core
             antibody positive, hepatitis B surface antibody negative (HBcAb+, HBsAb-)

          -  Use of prescription medication; over-the-counter medication; or herbal preparations
             containing St. John's Wort, kava, garlic, ginger, gingko biloba, or guarana within 14
             days prior to admission

          -  Consumption of grapefruit or grapefruit-containing foods or juices within 7 days prior
             to dosing or at any time during the study

          -  Have an average weekly alcohol intake that exceeds 15 units per week, or are unwilling
             to stop alcohol consumption for the duration of the study (1 unit = 12 oz or 360
             milliliter (mL) of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits)

          -  Consume 5 or more cups of coffee (or other beverages of comparable caffeine content)
             per day, on a habitual basis, or any subjects unwilling to adhere to study caffeine
             restrictions (no caffeine 48 hours prior to admission until the end of study

          -  Use of tobacco or nicotine-replacement products within the 6 months prior to study
             entry or at any time during the study

          -  Have donated blood of more than 500 mL within the last month

          -  Have participated in a 14C-study within the last 6 months prior to Check-in for this
             study. The total exposure from this study and the previous study must be within the
             Code of Federal Regulations (CFR) recommended levels considered safe (per 21 CFR
             361.1), for example less than 5,000 millirem (mrem)/year whole body annual exposure

          -  Exposure to significant radiation within 12 months prior to dose (for example, serial
             X-ray or computed tomography scans, barium meal, current employment in a job requiring
             radiation exposure monitoring)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559, Mon - Fri, 9AM - 5PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559), Mon - Fri, 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2011</study_first_submitted>
  <study_first_submitted_qc>February 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2011</study_first_posted>
  <results_first_submitted>March 10, 2017</results_first_submitted>
  <results_first_submitted_qc>March 10, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 21, 2017</results_first_posted>
  <last_update_submitted>May 15, 2017</last_update_submitted>
  <last_update_submitted_qc>May 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Absorption</keyword>
  <keyword>Distribution</keyword>
  <keyword>Metabolism</keyword>
  <keyword>Excretion</keyword>
  <keyword>Mass balance</keyword>
  <keyword>Metabolic profile</keyword>
  <keyword>Radiolabeled study</keyword>
  <keyword>14C</keyword>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>LY3009104 (Baricitinib)</title>
          <description>Single 10-milligram (mg) oral dose containing 100 microcuries of 14C-labeled LY3009104</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>LY3009104</title>
          <description>Single 10-mg oral dose containing 100 microcuries of 14C-labeled LY3009104</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.7" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of the Total Radioactive Dose Administered Excreted From Urine and Feces</title>
        <time_frame>Baseline up to 120 hours</time_frame>
        <population>Participants who took study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>LY3009104</title>
            <description>Single 10-mg oral dose containing 100 microcuries of 14C-labeled LY3009104</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of the Total Radioactive Dose Administered Excreted From Urine and Feces</title>
          <population>Participants who took study drug.</population>
          <units>percentage of total radioactivity</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Urine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.2" spread="6.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Feces</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.9" spread="4.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Pharmacokinetics: LY3009104 Area Under the Concentration-Time Curve From Time Zero to Infinity [AUC(0-∞)]</title>
        <time_frame>Baseline up to 48 hours</time_frame>
        <population>Participants who took study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>LY3009104</title>
            <description>Single 10-mg oral dose containing 100 microcuries of 14C-labeled LY3009104</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Pharmacokinetics: LY3009104 Area Under the Concentration-Time Curve From Time Zero to Infinity [AUC(0-∞)]</title>
          <population>Participants who took study drug.</population>
          <units>hour*nanomoles/liter(h*nmol/L)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1570" spread="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Pharmacokinetics: Radioactivity Area Under the Concentration-Time Curve From Time Zero to Infinity [AUC(0-∞)]</title>
        <time_frame>Baseline up to 48 hours</time_frame>
        <population>Participants who took study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>LY3009104</title>
            <description>Single 10-mg oral dose containing 100 microcuries of 14C-labeled LY3009104</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Pharmacokinetics: Radioactivity Area Under the Concentration-Time Curve From Time Zero to Infinity [AUC(0-∞)]</title>
          <population>Participants who took study drug.</population>
          <units>hour*nanomole-equivalents/kilogram</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1530" spread="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Pharmacokinetics: Maximum Observed LY3009104 Concentration (Cmax)</title>
        <time_frame>Baseline up to 48 hours</time_frame>
        <population>Participants who took study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>LY3009104</title>
            <description>Single 10-mg oral dose containing 100 microcuries of 14C-labeled LY3009104</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Pharmacokinetics: Maximum Observed LY3009104 Concentration (Cmax)</title>
          <population>Participants who took study drug.</population>
          <units>nanomoles/liter (nmol/L)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="227" spread="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Pharmacokinetics: Maximum Observed Radioactivity Concentration (Cmax)</title>
        <time_frame>Baseline up to 48 hours</time_frame>
        <population>Participants who took study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>LY3009104</title>
            <description>Single 10-mg oral dose containing 100 microcuries of 14C-labeled LY3009104</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Pharmacokinetics: Maximum Observed Radioactivity Concentration (Cmax)</title>
          <population>Participants who took study drug.</population>
          <units>nanomole-equivalents/milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="231" spread="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Pharmacokinetics: LY3009104 and Radioactivity Time to Maximum Observed Concentration (Tmax)</title>
        <time_frame>Baseline up to 48 hours</time_frame>
        <population>Participants who took study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>LY3009104</title>
            <description>Single 10-mg oral dose containing 100 microcuries of 14C-labeled LY3009104</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Pharmacokinetics: LY3009104 and Radioactivity Time to Maximum Observed Concentration (Tmax)</title>
          <population>Participants who took study drug.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LY3009104</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="1.00" upper_limit="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Radioactivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="1.00" upper_limit="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Dose of LY3009104 and LY3009104 Metabolites in Urine</title>
        <description>Percentages of LY3009104 (parent) and LY3009104 metabolites that were excreted in the urine are reported. Only those metabolites that were detectable in the urine are included in the report.</description>
        <time_frame>Baseline up to 48 hours</time_frame>
        <population>Participants who took study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>LY3009104</title>
            <description>Single 10-mg oral dose containing 100 microcuries of 14C-labeled LY3009104</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Dose of LY3009104 and LY3009104 Metabolites in Urine</title>
          <description>Percentages of LY3009104 (parent) and LY3009104 metabolites that were excreted in the urine are reported. Only those metabolites that were detectable in the urine are included in the report.</description>
          <population>Participants who took study drug.</population>
          <units>percentage of dose</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LY3009104</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite M3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite M10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite M22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Dose of LY3009104 and LY3009104 Metabolites in Feces</title>
        <description>Percentages of LY3009104 (parent) and LY3009104 metabolites that were excreted in the feces are reported. Only those metabolites that were detectable in the feces are included in the report.</description>
        <time_frame>Baseline up to 72 hours</time_frame>
        <population>Participants who took study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>LY3009104</title>
            <description>Single 10-mg oral dose containing 100 microcuries of 14C-labeled LY3009104</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Dose of LY3009104 and LY3009104 Metabolites in Feces</title>
          <description>Percentages of LY3009104 (parent) and LY3009104 metabolites that were excreted in the feces are reported. Only those metabolites that were detectable in the feces are included in the report.</description>
          <population>Participants who took study drug.</population>
          <units>percentage of dose</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LY3009104</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite M12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Total Radioactivity of LY3009104 and LY3009104 Metabolites in Plasma</title>
        <time_frame>Baseline up to 24 hours</time_frame>
        <population>Participants who took study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>LY3009104</title>
            <description>The percentage of total radioactivity of LY3009104 (parent) in the plasma after receiving a single 10-mg oral dose containing 100 microcuries of 14C-labeled LY3009104</description>
          </group>
          <group group_id="O2">
            <title>LY3009104 Metabolites</title>
            <description>The percentage of total radioactivity of all LY3009104 metabolites in the plasma after receiving a single 10-mg oral dose containing 100 microcuries of 14C-labeled LY3009104</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Total Radioactivity of LY3009104 and LY3009104 Metabolites in Plasma</title>
          <population>Participants who took study drug.</population>
          <units>percentage of total radioactivity</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.5"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>LY3009104</title>
          <description>Single 10-mg oral dose containing 100 microcuries of 14C-labeled LY3009104</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

